0001104659-19-073910.txt : 20191218
0001104659-19-073910.hdr.sgml : 20191218
20191218180044
ACCESSION NUMBER: 0001104659-19-073910
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20191216
FILED AS OF DATE: 20191218
DATE AS OF CHANGE: 20191218
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Farzaneh-Far Ramin
CENTRAL INDEX KEY: 0001688195
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37926
FILM NUMBER: 191293621
MAIL ADDRESS:
STREET 1: 87 CAMBRIDGEPARK DRIVE
STREET 2: C/O RA PHARMACEUTICALS, INC.
CITY: CAMBRIDGE
STATE: MA
ZIP: 02140
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Ra Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001481512
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 262908274
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 87 CAMBRIDGE PARK DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02140
BUSINESS PHONE: (617) 401-4060
MAIL ADDRESS:
STREET 1: 87 CAMBRIDGE PARK DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02140
4
1
a4.xml
4
X0306
4
2019-12-16
0
0001481512
Ra Pharmaceuticals, Inc.
RARX
0001688195
Farzaneh-Far Ramin
C/O RA PHARMACEUTICALS, INC.
87 CAMBRIDGEPARK DRIVE
CAMBRIDGE
MA
02140
0
1
0
0
Chief Medical Officer
COMMON STOCK
2019-12-16
4
M
0
1389
5.60
A
8521
D
COMMON STOCK
2019-12-16
4
M
0
9206
5.60
A
17727
D
COMMON STOCK
2019-12-16
4
S
0
10595
47.2252
D
7132
D
Stock Options (Right to buy)
5.60
2019-12-16
4
M
0
1389
0
D
2026-08-16
Common Stock
1389
15277
D
Stock Options (Right to buy)
5.60
2019-12-16
4
M
0
9206
0
D
2026-08-16
Common Stock
9206
101272
D
The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2019.
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $47.16 to $47.55. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
These stock options vest over a four (4) year period in 48 equal monthly installments at the end of each month following August 16, 2016.
These stock options vest a four (4) year period with the first twenty five percent (25%) of such shares vesting on the first anniversary of July 11, 2016, and the remaining shares vesting in equal monthly installments at the end of each month following the first anniversary of July 11, 2016 over the following thirty six (36) months, subject to the terms set forth in the applicable equity agreement.
/s/ David Lubner, Attorney-in-Fact for Ramin Farzaneh-Far
2019-12-18